Skip to main content
Premium Trial:

Request an Annual Quote

Celsius Therapeutics Raises $65M in Series A

NEW YORK (GenomeWeb) – Startup Celsius Therapeutics said today that it has raised $65 million in a Series A financing round.

The round was led by Third Rock Ventures, with participation from GV (formerly Google Ventures), Heritage Provider Network, Casdin Capital, Alexandria Venture Investments, and others.

The company plans to combine single-cell genomic sequencing of defined patient samples and computational analysis of massive datasets with complex algorithms to discover therapies for autoimmune diseases and cancer. The goal is to pick out specific cells that play a key role in disease and identify the genes that trigger their malfunction, allowing the company "to more efficiently identify specific targets for treating diseases in specific patients and ultimately develop medicines for those targets."

Celsius was cofounded by Aviv Regev, a professor of biology at the Massachusetts Institute of Technology and a core institute member, chair of the faculty, and director of the Klarman Cell Observatory at the Broad Institute of MIT and Harvard.  

The company has licensed technologies from the Broad Institute that are based on work by Regev and by Vijay Kuchroo, a professor of neurology at Harvard Medical School and an associated Broad member. This includes non-exclusive licenses to single-cell technologies and an exclusive license to early-stage therapeutic programs.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.